Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

EP: 1.Evolving Guidelines: Impact of Gene Therapy and BCG Failure Redefinitions on High-Risk NMIBC Patient Management

EP: 2.Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC

Now Viewing

EP: 3.Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

EP: 4.Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

EP: 5.Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

EP: 6.Reducing Clinical Resource Burden: Impact of Less Frequent NMIBC Therapy Administration

EP: 7.How Community-Based Gene Therapy Is Changing Treatment and Improving Quality of Life for Patients With BCG-Unresponsive NMIBC

EP: 8.Understanding NMIBC and Its Risk Factors

EP: 9.Navigating Treatment Burden in NMIBC

EP: 10.When BCG Falls Short: What’s Next for NMIBC Patients?

EP: 11.A New Era: The Rise of Gene Therapy in NMIBC

EP: 12.Where Do We Go From Here? Overcoming Barriers in NMIBC Care

EP: 13.Bridging the Gap Between Clinical Trial Evidence and Real-World Practice in NMIBC

EP: 14.Coverage Criteria and Clinical Evidence Used to Shape Health Plan Formulary Decisions in BCG-Unresponsive NMIBC

EP: 15.Prioritizing Safety and Efficacy: Role of Guidelines in NMIBC Formulary Decisions

EP: 16.Evaluating Cost-Effectiveness of NMIBC Therapies From a Health Plan Perspective

EP: 17.Leveraging Real-World Evidence in NMIBC Therapy Evaluations

Video content above is prompted by the following:

Real-world evidence significantly influences gene therapy adoption in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) through demonstrated durability and tolerability profiles. The two viral gene therapies in development (one FDA-approved, one pending) utilize adenovirus-based vectors that are exceptionally well tolerated, with patients experiencing minimal impact on urinary quality of life beyond temporary symptoms lasting a few days. This favorable tolerability profile represents a significant advantage over other intravesical therapies that may cause more persistent urinary symptoms.

Long-term oncologic outcomes show meaningful success rates, with 30% to 40% of patients achieving disease-free survival despite the inherent challenges of treating BCG-unresponsive disease. While most patients still experience treatment failure, the substantial minority who achieve durable responses provides compelling evidence for continued therapy adoption. This success rate, comparable to a baseball batting average, represents a meaningful improvement for patients who otherwise face limited treatment options.

Treatment selection and sequencing remain significant challenges due to limited comparative data. The American Urological Association guidelines assign a Grade C recommendation with conditional approval, indicating uncertain net benefits and harms. This uncertainty underscores the critical need for comparative randomized trials to guide evidence-based treatment selection. Until such data become available, clinical decision-making relies on individual patient factors, provider experience and institutional protocols rather than standardized treatment algorithms.